Business context and reporting period
Corcept Therapeutics Incorporated’s Form 10-K covers the fiscal year ended December 31, 2012; it is an annual filing, not a standalone fourth-quarter report. Corcept develops and commercializes medicines targeting cortisol-related metabolic and psychiatric disorders. FDA-approved Korlym (mifepristone) became available in April 2012 for certain adults with endogenous Cushing’s syndrome and hyperglycemia. The company also has an ongoing Phase 3 study of mifepristone for psychotic depression and is developing selective GR-II antagonists.
Financial results and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Net product sales | $3.307 million | None |
| Cost of sales | $0.091 million | None |
| Gross profit / margin | $3.216 million / 97.2% | Not applicable |
| Research and development expense | $14.074 million | $21.001 million |
| Selling, general and administrative expense | $25.414 million | $11.331 million |
| Operating loss | $36.272 million | $32.332 million |
| Net loss | $38.048 million | $32.354 million |
| Net loss per share, basic and diluted | $0.41 | $0.39 |
| Net cash used in operations | $36.020 million | $27.400 million |
| Cash and cash equivalents at year-end | $93.032 million | $39.635 million |
| Working capital at year-end | $86.703 million | $34.749 million |
The reported gross margin is not representative of fully burdened production economics: much of the manufacturing cost of product sold had been expensed before approval. Fourth-quarter 2012 product sales were $1.377 million, gross profit was $1.358 million, net loss was $11.124 million and loss per share was $0.11.
Year-end assets were $99.166 million and stockholders’ equity was $61.777 million. Cash increased primarily through financing: net proceeds from stock and warrant transactions were $59.708 million, and the company received $30 million under a capped royalty financing agreement. That agreement is recorded as a long-term obligation with a $31.680 million carrying value at year-end; total payments to the financing provider are capped at $45 million.
Material changes versus the prior comparable period
- Korlym generated the company’s first meaningful product revenue in 2012, following its April launch.
- Net loss widened by $5.694 million. SG&A rose substantially as Corcept built commercialization capabilities and incurred approval-related compensation and launch costs.
- R&D expense fell by $6.927 million, mainly reflecting reduced NDA-preparation and manufacturing costs, partly offset by higher psychotic-depression trial spending.
- Operating cash use increased by $8.620 million. The year-end cash balance rose due to equity issuance and royalty financing, rather than positive operating cash flow.
Outlook, commentary, risks and unusual items
- Management expected 2013 R&D expense and SG&A expense to increase, with operating cash use also expected to rise, as the company expands commercialization, psychotic-depression trial enrollment and selective-antagonist development. Corcept did not provide revenue guidance.
- Management targeted enrollment sufficient for a possible interim analysis of the ongoing Phase 3 Study 14 by year-end 2013 and planned to expand the study to approximately 20 sites by the end of Q1 2013. The analysis was not assured, and results could be negative or inconclusive.
- Korlym commercialization is early-stage and faces adoption, reimbursement, pricing, competition and product-return uncertainty. Novartis’s Signifor was approved in 2012 for a subset of Cushing’s syndrome patients.
- Supply is a key risk: the active ingredient had a single-source manufacturer under an agreement expiring in June 2013, while the company was negotiating its continuation. The original tablet manufacturer had suspended production during relocation; an alternate site was FDA-approved, but a commercial supply agreement was still being negotiated.
- The $30 million royalty financing requires payments equal to 20% of covered-product sales and certain licensing receipts, subject to stated caps for 2013–2015. Specified covenant or information failures, if not cured, can raise the rate to 50% and remove caps; a change of control or U.S. licensing of Korlym can accelerate the unpaid amount.
- Other notable items: FDA approval triggered performance-based stock compensation and employee bonuses; the FDA later advised that a REMS program was not necessary, although Corcept retained elements as its patient access and reimbursement program. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Subsequent Korlym sales, patient uptake, reimbursement coverage, channel inventory and return reserves, given the limited launch history and concentration in two related distribution customers.
- Progress and results of Study 14, including enrollment, any interim-analysis decision and implications for trial timing and spending.
- Execution of the API and tablet manufacturing arrangements, supply continuity and production costs as pre-approval inventory is used.
- Actual payments and covenant compliance under the Biopharma financing agreement, including the potential impact of accelerated repayment provisions.
- Cash runway relative to planned operating spending and any additional financing needs; the company reported a $246.6 million accumulated deficit and a history of losses.